250 related articles for article (PubMed ID: 37676710)
1. Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer.
Santasusagna S; Zhu S; Jawalagatti V; Carceles-Cordon M; Ertel A; Garcia-Longarte S; Song WM; Fujiwara N; Li P; Mendizabal I; Petrylak DP; Kelly WK; Reddy EP; Wang L; Schiewer MJ; Lujambio A; Karnes J; Knudsen KE; Cordon-Cardo C; Dong H; Huang H; Carracedo A; Hoshida Y; Rodriguez-Bravo V; Domingo-Domenech J
Cancer Discov; 2023 Dec; 13(12):2584-2609. PubMed ID: 37676710
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
3. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer.
Wang H; Li N; Liu Q; Guo J; Pan Q; Cheng B; Xu J; Dong B; Yang G; Yang B; Wang X; Gu Y; Zhang G; Lian Y; Zhang W; Zhang M; Li T; Zang Y; Tan M; Li Q; Wang X; Yu Z; Jiang J; Huang H; Qin J
Cancer Cell; 2023 Jul; 41(7):1345-1362.e9. PubMed ID: 37352863
[TBL] [Abstract][Full Text] [Related]
5. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
6. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
Wadosky KM; Koochekpour S
Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
[TBL] [Abstract][Full Text] [Related]
7. Double-layer omics analysis of castration- and X-ray-resistant prostate cancer cells.
Iwanaga M; Kawamura H; Kubo N; Mizukami T; Oike T; Sato H; Miyazawa Y; Sekine Y; Kawabata-Iwakawa R; Nishiyama M; Ohno T; Nakano T
J Radiat Res; 2022 Jul; 63(4):585-590. PubMed ID: 35589101
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer.
Chen X; Shao Y; Wei W; Zhu S; Li Y; Chen Y; Li H; Tian H; Sun G; Niu Y; Shang Z
Cell Death Dis; 2022 Nov; 13(11):927. PubMed ID: 36335093
[TBL] [Abstract][Full Text] [Related]
9. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
10. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
Lin SR; Wen YC; Yeh HL; Jiang KC; Chen WH; Mokgautsi N; Huang J; Chen WY; Liu YN
Oncogene; 2020 Oct; 39(44):6757-6775. PubMed ID: 32963351
[TBL] [Abstract][Full Text] [Related]
11. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
12. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Hawley JE; Obradovic AZ; Dallos MC; Lim EA; Runcie K; Ager CR; McKiernan J; Anderson CB; Decastro GJ; Weintraub J; Virk R; Lowy I; Hu J; Chaimowitz MG; Guo XV; Zhang Y; Haffner MC; Worley J; Stein MN; Califano A; Drake CG
Cancer Cell; 2023 Nov; 41(11):1972-1988.e5. PubMed ID: 37922910
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
15. Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46.
Liu YN; Niu S; Chen WY; Zhang Q; Tao Y; Chen WH; Jiang KC; Chen X; Shi H; Liu A; Li J; Li Y; Lee YC; Zhang X; Huang J
Clin Cancer Res; 2019 Jul; 25(13):4128-4140. PubMed ID: 30962287
[TBL] [Abstract][Full Text] [Related]
16. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
Coutinho I; Day TK; Tilley WD; Selth LA
Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
[TBL] [Abstract][Full Text] [Related]
18. Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.
Zhu W; Wan F; Xu W; Liu Z; Wang J; Zhang H; Huang S; Ye D
Clin Transl Med; 2022 Sep; 12(9):e1028. PubMed ID: 36169095
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic Plasticity - Alternate Transcriptional Programs Driving Treatment Resistant Prostate Cancer.
Nanda JS; Koganti P; Perri G; Ellis L
Crit Rev Oncog; 2022; 27(1):45-60. PubMed ID: 35993978
[TBL] [Abstract][Full Text] [Related]
20. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]